COVID-19 and RAS: Unravelling an Unclear Relationship.
Damiano D'ArdesAndrea BoccatondaIlaria RossiMaria Teresa GuagnanoFrancesca SantilliFrancesco CipolloneMarco BucciPublished in: International journal of molecular sciences (2020)
The renin-angiotensin system (RAS) plays a main role in regulating blood pressure and electrolyte and liquid balance. Previous evidence suggests that RAS may represent an important target for the treatment of lung pathologies, especially for acute respiratory distress syndrome and chronic fibrotic disease. The scientific community has recently focused its attention on angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease (COVID-19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting.
Keyphrases
- coronavirus disease
- angiotensin converting enzyme
- acute respiratory distress syndrome
- angiotensin ii
- blood pressure
- sars cov
- end stage renal disease
- wild type
- extracorporeal membrane oxygenation
- mechanical ventilation
- ejection fraction
- respiratory syndrome coronavirus
- ionic liquid
- newly diagnosed
- chronic kidney disease
- healthcare
- peritoneal dialysis
- working memory
- mental health
- prognostic factors
- idiopathic pulmonary fibrosis
- skeletal muscle
- adipose tissue
- heart rate
- hypertensive patients
- insulin resistance
- solid state
- community acquired pneumonia